Amgen Canada Inc.

What they're asking for

In the registry's own words. Descriptions are only filed for meetings since mid-2024.

1. Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.

   June 9, 2026 · Ali Ehsassi · Liberal · Science and Technology; Economic Development

2. Communicating with government officials about international trade agreements, including the Canada-United States-Mexico Agreement (CUSMA), formerly known as the North American Free Trade Agreement (NAFTA), more specifically as it relates to trade in the life sciences and biopharmaceutical sectors.

   February 23, 2026 · Karim Bardeesy · Liberal · Health; International Trade

3. Communicating with government officials about the implementation, renewal and expansion of the "National Strategy for Drugs for Rare Diseases" (2023).

   November 25, 2025 · Tom Kmiec · Conservative · Health; Science and Technology

4. Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.

   October 21, 2025 · Maggie Chi · Liberal · Health; International Trade; Science and Technology; Economic Development

5. Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.

   July 7, 2025 · Tom Kmiec · Conservative · Health; Science and Technology; Taxation and Finance

Full meeting log

19 MP-directed communications since January 2024, from the Registry of Lobbyists.